Published in N Engl J Med on November 19, 2013
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin (EU-PACT) | NCT01119300
Warfarin Anticoagulation in Patients in Sub-Saharan Africa (War-PATH) | NCT03512080
Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes | NCT03797534
Association Between Genetic Variant Scores and Warfarin Effect (AWARE1) | NCT03894878
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med (2013) 2.00
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood (2014) 1.63
Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet Med (2015) 1.59
Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc (2015) 1.51
Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping. Indian J Pharmacol (2016) 1.40
Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther (2017) 1.39
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.37
Global implementation of genomic medicine: We are not alone. Sci Transl Med (2015) 1.30
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.06
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 1.05
Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med (2014) 1.02
Pharmacogenetics and coumarin dosing--recalibrating expectations. N Engl J Med (2013) 0.99
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J (2014) 0.97
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet (2015) 0.94
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet (2015) 0.93
An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D. Mol Diagn Ther (2014) 0.91
Pharmacogenomics: Current State-of-the-Art. Genes (Basel) (2014) 0.90
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Genetic testing in cardiovascular diseases. Curr Opin Cardiol (2014) 0.88
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88
Individualized medicine enabled by genomics in Saudi Arabia. BMC Med Genomics (2015) 0.87
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One (2014) 0.86
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? Pharmacogenomics (2014) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
Pharmacogenomics and adverse drug reactions in children. Front Genet (2014) 0.86
Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. Dtsch Arztebl Int (2014) 0.83
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials. Br J Clin Pharmacol (2015) 0.82
Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther (2014) 0.82
Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med (2015) 0.82
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Progress towards the integration of pharmacogenomics in practice. Hum Genet (2014) 0.81
Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed Res Int (2014) 0.81
Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J (2015) 0.81
The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response. Dis Markers (2014) 0.81
Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J (2015) 0.81
Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81
The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet (2016) 0.81
APOE ε variants increase risk of warfarin-related intracerebral hemorrhage. Neurology (2014) 0.80
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Anticoagulation therapy: genotype-guided anticoagulation therapy-the jury is still out. Nat Rev Cardiol (2013) 0.80
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol (2015) 0.80
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J (2014) 0.79
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics (2016) 0.79
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther (2016) 0.79
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med (2016) 0.78
Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. Curr Psychiatry Rev (2014) 0.78
Personalized medicine and stroke prevention: where are we? Vasc Health Risk Manag (2015) 0.78
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy (2016) 0.78
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Eur J Clin Pharmacol (2014) 0.78
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience. Pediatr Cardiol (2015) 0.78
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78
Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J (2015) 0.77
In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother (2015) 0.77
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clin Pharmacokinet (2016) 0.77
Challenges to integrating pharmacogenetic testing into medication therapy management. J Manag Care Spec Pharm (2015) 0.77
Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement. PLoS One (2014) 0.77
Personalized genomes and cardiovascular disease. Cold Spring Harb Perspect Med (2014) 0.77
Personalized medicine in thrombosis: back to the future. Blood (2016) 0.77
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics. Pharmacogenet Genomics (2015) 0.77
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med (2017) 0.77
Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther (2017) 0.77
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther (2017) 0.76
Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists. Pharmgenomics Pers Med (2015) 0.76
Improved drug therapy: triangulating phenomics with genomics and metabolomics. Hum Genomics (2014) 0.76
Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII. Hippokratia (2015) 0.76
Genotype-guided dosing of vitamin K antagonists. N Engl J Med (2014) 0.76
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics (2015) 0.76
Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. PeerJ (2016) 0.76
Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics (2016) 0.76
Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm (2016) 0.76
Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med (2015) 0.76
Lack of Association of Clinical Factors (SAMe-TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality. J Stroke (2015) 0.76
Do physicians think genomic medicine will be useful for patient care? Per Med (2015) 0.76
STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pac Symp Biocomput (2016) 0.75
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. Diabetes Care (2016) 0.75
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J (2016) 0.75
Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. Paediatr Drugs (2016) 0.75
Using pharmacogenetics in real time to guide therapy: the warfarin example. Clin Genet (2014) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record. Curr Genet Med Rep (2014) 0.75
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75
A brighter future for the implementation of pharmacogenomic testing. Eur J Hum Genet (2016) 0.75
The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. PLoS One (2016) 0.75
Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. Appl Clin Inform (2016) 0.75
SDF1 Polymorphisms Influence Outcome in Patients with Symptomatic Cardiovascular Disease. PLoS One (2016) 0.75
Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. BMC Cardiovasc Disord (2016) 0.75
Implementing Precision Medicine: The Ethical Challenges. Trends Pharmacol Sci (2016) 0.75
Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm (2016) 0.75
Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature. BMJ Open (2016) 0.75
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract (2004) 8.06
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet (2007) 6.20
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (2010) 5.70
Infrared ear thermometry compared with rectal thermometry in children: a systematic review. Lancet (2002) 5.18
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78
Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One (2013) 4.38
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med (2011) 3.62
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One (2009) 3.45
Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27
Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev (2011) 3.23
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet (2004) 3.00
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2010) 2.95
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med (2008) 2.42
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood (2006) 2.27
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev (2015) 2.13
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol (2010) 1.97
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med (2005) 1.86
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 1.83
Primary school-based behavioural interventions for preventing caries. Cochrane Database Syst Rev (2013) 1.80
Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther (2005) 1.79
Familial and cultural perceptions and beliefs of oral hygiene and dietary practices among ethnically and socio-economicall diverse groups. Community Dent Health (2004) 1.78
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol (2011) 1.73
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol (2002) 1.73
Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost (2005) 1.70
Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups. Trials (2013) 1.69
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J (2011) 1.67
The COMET Initiative database: progress and activities from 2011 to 2013. Trials (2014) 1.64
Bias due to changes in specified outcomes during the systematic review process. PLoS One (2010) 1.61
High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. J Clin Epidemiol (2005) 1.60
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) (2011) 1.59
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol (2006) 1.54
Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia (2002) 1.53
Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials (2012) 1.49
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol (2002) 1.49
Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials (2013) 1.47
CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol (2003) 1.47
Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin. Thromb Res (2013) 1.46
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res (2012) 1.46
APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics (2006) 1.45
Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One (2011) 1.45
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev (2015) 1.39
Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. PLoS One (2009) 1.36
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology (2004) 1.35
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. Stat Med (2012) 1.34
International comparisons of health inequalities in childhood dental caries. Community Dent Health (2004) 1.34
Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database Syst Rev (2012) 1.32
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics (2006) 1.32
The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol (2004) 1.31
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther (2004) 1.31
Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials (2009) 1.28
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol (2012) 1.28
Assessing the potential for outcome reporting bias in a review: a tutorial. Trials (2010) 1.26
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
Communication about children's clinical trials as observed and experienced: qualitative study of parents and practitioners. PLoS One (2011) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood (2011) 1.22
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther (2003) 1.21